The effect of magnesium in controlling neuropsychiatric complications of convulsive patients

Investigating the effect of magnesium supplementation in controlling neuropsychiatric complications of convulsive patients treated with levetiracetam

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250410065274N1

Enrollment

160

Registered

2025-08-04

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

convulsive. Conversion disorder with seizures or convulsions

Interventions

Intervention 1: Intervention group: Levetiracetam 500 mg daily plus magnesium supplement in the form of 250 mg magnesium tablets (Ruzdaro Pharmaceutical Company) daily for three months. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: History of seizures Age above 18 years Taking 500 mg of Levetiractam daily

Exclusion criteria

Exclusion criteria: Blood magnesium level above 3 mmol/L Taking other antiepileptic drugs Simultaneous use of drugs that have psychiatric side effects History of kidney failure and heart disease

Design outcomes

Primary

Measure	Time frame
Neuropsychiatric complications. Timepoint: The beginning of the study, one month later, and the end of the third month. Method of measurement: SCL90 Psychiatric Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Moradi

Ghoum University of Medical Sciences

moradim46@yahoo.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026